Introduction: Treatment failure and relapse rates are more likely to occur when there is isoniazid (INH) resistance. So, we can no longer ignore the problem of isoniazid mono-resistance. It is pertinent to control the spread of primary INH resistance and prevent secondary resistance.
Aim: This study aims to evaluate subjects' clinical, demographic, and genetic characteristics and explore their treatment outcomes.
Methods: All data of isoniazid mono-resistant tuberculosis (TB) patients, which were maintained in the electronic database of mandatory notifications (NIKSHAY Portal) between 2017 and 2022, were reviewed. A total of 54 patients were included after excluding five patients with ongoing treatment.
Results: Of 54 patients, 41 (75.9%) were cured, which was classified under favorable outcome, and the rest were classified under unfavorable outcome. Phenotypic, high-level mutation () was found in 48 (88.9%) patients. Kaplan-Meier curves show that survival probabilities increase in weeks with regular intake of drugs.
Conclusion: Our study found that those with younger ages and males were more affected. We found favorable outcomes in the majority of patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439306 | PMC |
http://dx.doi.org/10.7759/cureus.42166 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!